Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study found that Smad7 perturbs hair follicle development while promoting sebaceous gland formation by antagonizing Wnt/β-catenin signaling in transgenic mice.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

This study identified four genetic loci on chromosomes 6, 10, 16, and 18 that may contribute to susceptibility for alopecia areata and suggested shared genetic factors with psoriasis.

This review discusses the autoimmune nature of alopecia areata, potential therapeutic targets, and highlights the need for further studies on immunomodulatory treatments and genetic factors, but it reports no new clinical results.

In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.

This article discusses the potential of RNA-based biopesticides for sustainable agriculture and reports no new experimental results; it highlights the need for improved delivery systems and regulatory development to enhance deployment.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This review examines various skin pigmentation disorders, their causes, and potential treatments, detailing 25 plants, 4 marine species, and 17 clinically tested topical and oral medications for managing these conditions.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that alopecia in VDR-null mice persists despite undetectable vitamin D levels, indicating a defect in epithelial-mesenchymal communication due to the absence of ligand-independent receptor function.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.

This study suggests that applying topical Tempol to the scalp before whole brain radiation may protect against radiation-induced alopecia and is safe and well-tolerated.

This study observed that alopecia areata can be induced and serially transferred in C3H/HeJ mice using skin grafts, providing a useful model for studying the disease in humans.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

This study found that frontal fibrosing alopecia and lichen planopilaris have similar histopathological features, but FFA exhibits more prominent apoptosis and less inflammation with spared interfollicular epidermis.

In this study, researchers found that in late pregnancy, the neuroactive progesterone metabolite allopregnanolone inhibits HPA axis responses to immune challenges via an opioid-mediated mechanism.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.

This study found that K17 is crucial for the structural integrity and survival of hair-producing cells, with K17 null mice developing alopecia due to hair fragility and follicular alterations.

The document describes how to tell different types of non-scarring hair loss apart by looking at hair and scalp tissue under a microscope.

This review discusses the potential autoimmune pathogenesis and various contributing factors of alopecia areata, noting that current treatments remain palliative while emerging therapies offer new hope for extensive cases.

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.

This study found that normalizing mineral ion levels in vitamin D receptor-ablated mice prevented hyperparathyroidism, rickets, and osteomalacia, but alopecia persisted, indicating a separate role for the receptor in hair growth.